GENNIEFY
Market News
Latest financial news and analysis from global markets
CRSP
Is It Time To Reconsider CRISPR Therapeutics (CRSP) After A 58% One Year Rally?
Before you decide whether CRISPR Therapeutics stock looks attractive at around US$52.38, it helps to ask a simple question: what are you actually paying for compared with what the business might be worth? Over the last week the stock return is 0.6%, over the last month it is 5.8%, and over the last year it is 58.0%, while the year-to-date return is a 2.6% decline and the three- and five-year returns are 17.4% and 49.4% declines respectively, which may catch the eye of both momentum fans and...
XAU/USD
Assessing Agnico Eagle Mines (AEM) After A 51% Year Return And Recent Pullback
Wondering whether Agnico Eagle Mines is offering fair value at the current price, or if the recent run has already baked in most of the upside, starts with understanding how the stock is being priced today. The stock last closed at US$178.14, with returns of 4.5% year to date and 51.1% over 1 year, set against shorter term moves of a 5.9% decline over 7 days and a 14.6% decline over 30 days that may be reshaping risk and return expectations. Recent coverage has focused on Agnico Eagle Mines...
HOOD
Robinhood (HOOD) Receives In-Principle Approval to Launch Brokerage Services in Singapore
Robinhood Markets, Inc. (NASDAQ:HOOD) is one of the best young stocks to buy and hold for the next decade. On April 23, Robinhood received in-principle approval/IPA from the Monetary Authority of Singapore/MAS to launch brokerage services, marking a step in the company’s international expansion. This regulatory milestone will eventually allow Robinhood to offer a range […]
AMZN
Jeff Bezos Asked Warren Buffett Why People Don't Just Copy His Investing Strategy —'My Approach Is A Get Rich Slowly Scheme…People Don't Like Those'
Most people don't miss the strategy. They miss the patience. Amazon founder Jeff Bezos made that clear while recounting a conversation with Berkshire Hathaway Chair Warren Buffett. "I once asked Warren Buffett, why don't more people copy your investment strategy?...
AAPL
Apple faces supply strain from strong Mac demand
Strong demand runs ahead of chip availability
USDCUSD
Circle Internet Group (CRCL) Integrates USDC and AI into Kyriba’s Treasury Platform
Circle Internet Group Inc. (NYSE:CRCL) is one of the best young stocks to buy and hold for the next decade. On April 28, Circle and Kyriba partnered to integrate USDC capabilities directly into Kyriba’s treasury management platform, enabling enterprises to use digital dollars within their existing workflows. Central to this collaboration is Kyriba’s Trusted Agentic […]
MSFT
Medline (MDLN) Launches AI-Powered Mpower Platform to Enhance Healthcare Supply Chain Resiliency
Medline Inc. (NASDAQ:MDLN) is one of the best young stocks to buy and hold for the next decade. On May 4, Medline officially launched Mpower, a cloud-based, AI-powered digital control tower designed to enhance supply chain resiliency for healthcare providers. Developed in collaboration with Microsoft and informed by feedback from US health systems, the platform […]
PFE
Can Pfizer Stock Outrun A $17B Revenue Void?
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
MRK
Can Pfizer Stock Outrun A $17B Revenue Void?
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
JNJ
Can Pfizer Stock Outrun A $17B Revenue Void?
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
MS
Morgan Stanley tops construction sector M&A rankings by value in Q1 2026
Morgan Stanley ranked first by value after advising on deals worth $23.7bn during the quarter.
ETHUSDT
Investor Tom Lee Says The 'Crypto Spring' Has Begun
Famed investor Tom Lee, who is chair of BitMine Immersion Technologies (NYSE: $BMNR), says a new “crypto spri...